%0 Journal Article
%T A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
%A Andrew Owen
%A Christine Sekaggya-Wiltshire
%A Julian P Kaboggoza
%A Marta Boffito
%A Megan Neary
%A Mohammed Lamorde
%A Myra McClure
%A Pedro Ayuso
%A Shadia Nakalema
%A Xinxhu Wang
%J Archive of "Open Forum Infectious Diseases".
%D 2019
%R 10.1093/ofid/ofz035
%X To the Editor¡ªThe ENCORE-1 study demonstrated noninferiority of efavirenz 400 mg once daily (EFV400) when compared with the standard dose (EFV600) [1]. Based on these data, the World Health Organization (WHO) recommends EFV400 as an alternative first-line antiretroviral drug but restricts its use to nonpregnant patients and patients without tuberculosis (TB) [2]. However, a recently published study in United Kingdom human immunodeficiency virus (HIV)-positive patients without TB found EFV concentrations to be adequate when EFV400 was coadministered with rifampicin and isoniazid (RH) [3]. To confirm these results in a TB-infected population, we conducted an open label, nonrandomized, pharmacokinetic study in HIV/TB coinfected patients in Uganda
%K HIV
%K isoniazid/rifampicin
%K low-dose efavirenz
%K pharmacokinetics
%K tuberculosis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386798/